Active Not Recruiting PHASE2 INTERVENTIONAL 2-arm NCT03816163

A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer

A Phase 2, Open-Label, Randomized Study to Assess the Efficacy and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

Sponsor: Astellas Pharma Global Development, Inc.

Conditions Metastatic Pancreatic Adenocarcinoma Metastatic Pancreatic Cancer Pancreatic Cancer

Interventions gemcitabine nab-paclitaxel zolbetuximab

Updated 68 times since 2019 Last updated: Mar 10, 2026 Started: Mar 15, 2019 Primary completion: Aug 31, 2026 Completion: Aug 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Metastatic Pancreatic Adenocarcinoma and Metastatic Pancreatic Cancer, this trial is ongoing. The trial is conducted by Astellas Pharma Global Development, Inc. and has accumulated 68 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

68 versions recorded

Mar 2026 — Present [monthly]

Active Not Recruiting PHASE2
Feb 2026 — Mar 2026 [monthly]

Active Not Recruiting PHASE2
Jan 2026 — Feb 2026 [monthly]

Active Not Recruiting PHASE2
Nov 2025 — Jan 2026 [monthly]

Active Not Recruiting PHASE2
Sep 2025 — Nov 2025 [monthly]

Active Not Recruiting PHASE2

▶ Show 63 earlier versions

May 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE2
Apr 2025 — May 2025 [monthly]

Active Not Recruiting PHASE2
Feb 2025 — Apr 2025 [monthly]

Active Not Recruiting PHASE2
Dec 2024 — Feb 2025 [monthly]

Active Not Recruiting PHASE2
Oct 2024 — Dec 2024 [monthly]

Active Not Recruiting PHASE2
Sep 2024 — Oct 2024 [monthly]

Active Not Recruiting PHASE2
Aug 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE2
Jul 2024 — Aug 2024 [monthly]

Active Not Recruiting PHASE2
Jun 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE2
May 2024 — Jun 2024 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Apr 2024 — May 2024 [monthly]

Recruiting PHASE2
Mar 2024 — Apr 2024 [monthly]

Recruiting PHASE2
Feb 2024 — Mar 2024 [monthly]

Recruiting PHASE2
Jan 2024 — Feb 2024 [monthly]

Recruiting PHASE2
Nov 2023 — Jan 2024 [monthly]

Recruiting PHASE2
Oct 2023 — Nov 2023 [monthly]

Recruiting PHASE2
Sep 2023 — Oct 2023 [monthly]

Recruiting PHASE2
Aug 2023 — Sep 2023 [monthly]

Recruiting PHASE2
Jul 2023 — Aug 2023 [monthly]

Recruiting PHASE2
Jun 2023 — Jul 2023 [monthly]

Recruiting PHASE2
May 2023 — Jun 2023 [monthly]

Recruiting PHASE2
Apr 2023 — May 2023 [monthly]

Recruiting PHASE2
Feb 2023 — Apr 2023 [monthly]

Recruiting PHASE2
Jan 2023 — Feb 2023 [monthly]

Recruiting PHASE2
Dec 2022 — Jan 2023 [monthly]

Recruiting PHASE2
Nov 2022 — Dec 2022 [monthly]

Recruiting PHASE2
Sep 2022 — Nov 2022 [monthly]

Recruiting PHASE2
Jun 2022 — Sep 2022 [monthly]

Recruiting PHASE2
May 2022 — Jun 2022 [monthly]

Recruiting PHASE2
Apr 2022 — May 2022 [monthly]

Recruiting PHASE2
Mar 2022 — Apr 2022 [monthly]

Recruiting PHASE2
Feb 2022 — Mar 2022 [monthly]

Recruiting PHASE2
Jan 2022 — Feb 2022 [monthly]

Recruiting PHASE2
Dec 2021 — Jan 2022 [monthly]

Recruiting PHASE2
Nov 2021 — Dec 2021 [monthly]

Recruiting PHASE2
Oct 2021 — Nov 2021 [monthly]

Recruiting PHASE2
Sep 2021 — Oct 2021 [monthly]

Recruiting PHASE2
Jun 2021 — Sep 2021 [monthly]

Recruiting PHASE2
May 2021 — Jun 2021 [monthly]

Recruiting PHASE2
Apr 2021 — May 2021 [monthly]

Recruiting PHASE2
Mar 2021 — Apr 2021 [monthly]

Recruiting PHASE2
Feb 2021 — Mar 2021 [monthly]

Recruiting PHASE2
Jan 2021 — Feb 2021 [monthly]

Recruiting PHASE2
Dec 2020 — Jan 2021 [monthly]

Recruiting PHASE2
Nov 2020 — Dec 2020 [monthly]

Recruiting PHASE2
Oct 2020 — Nov 2020 [monthly]

Recruiting PHASE2
Sep 2020 — Oct 2020 [monthly]

Recruiting PHASE2
Aug 2020 — Sep 2020 [monthly]

Recruiting PHASE2
Jul 2020 — Aug 2020 [monthly]

Recruiting PHASE2
Jun 2020 — Jul 2020 [monthly]

Recruiting PHASE2
May 2020 — Jun 2020 [monthly]

Recruiting PHASE2
Mar 2020 — May 2020 [monthly]

Recruiting PHASE2
Feb 2020 — Mar 2020 [monthly]

Recruiting PHASE2
Dec 2019 — Feb 2020 [monthly]

Recruiting PHASE2
Nov 2019 — Dec 2019 [monthly]

Recruiting PHASE2
Oct 2019 — Nov 2019 [monthly]

Recruiting PHASE2
Sep 2019 — Oct 2019 [monthly]

Recruiting PHASE2
Aug 2019 — Sep 2019 [monthly]

Recruiting PHASE2
Jul 2019 — Aug 2019 [monthly]

Recruiting PHASE2
Jun 2019 — Jul 2019 [monthly]

Recruiting PHASE2
Apr 2019 — Jun 2019 [monthly]

Recruiting PHASE2
Mar 2019 — Apr 2019 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Feb 2019 — Mar 2019 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Astellas Pharma Global Development, Inc.

Data source: Astellas Pharma Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ankara, Turkey (Türkiye) , Aquitaine, France , Barcelona, Spain , Basking Ridge, United States , Bayonne, France , Beijing, China , Besançon, France , Boca Raton, United States , Bordeaux, France , Brest, France and 104 more locations